Ralph P Insinga
Overview
Explore the profile of Ralph P Insinga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Insinga R, Feliciano J, Qiao N, Vandormael K, Zhang Y
J Med Econ
. 2021 Jun;
24(1):792-805.
PMID: 34098842
Objective: Pembrolizumab + chemotherapy substantially extends life expectancy for metastatic non-small cell lung cancer (NSCLC) patients. Its cost-effectiveness (CE) was previously evaluated based on interim trial analyses (follow-up ∼1 year)....
2.
Huang M, Insinga R, Burke T, Zhang Y, de Lima Lopes G
Lung Cancer
. 2020 Jun;
146:385-386.
PMID: 32593484
No abstract available.
3.
Huang M, de Lima Lopes G, Insinga R, Burke T, Ejzykowicz F, Zhang Y, et al.
Immunotherapy
. 2019 Nov;
11(17):1463-1478.
PMID: 31738117
This analysis aimed to evaluate the cost-effectiveness of pembrolizumab monotherapy as first-line treatment in advanced non-small-cell lung cancer patients with a programmed death ligand 1 (PD-L1) tumor proportion score ≥1%...
4.
Loong H, Wong C, Leung L, Dhankhar P, Insinga R, Chandwani S, et al.
Pharmacoecon Open
. 2019 Sep;
4(2):235-247.
PMID: 31531842
Background: Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1 tumor...
5.
Insinga R, Vanness D, Feliciano J, Vandormael K, Traore S, Ejzykowicz F, et al.
Curr Med Res Opin
. 2019 Jan;
35(7):1241-1256.
PMID: 30649973
To describe the cost-effectiveness of pembrolizumab plus chemotherapy (carboplatin and paclitaxel or nab-paclitaxel; P + C) in metastatic, squamous, non-small-cell lung cancer (NSCLC) patients in the US. A model comparing...
6.
Insinga R, Vanness D, Feliciano J, Vandormael K, Traore S, Burke T
J Med Econ
. 2018 Sep;
21(12):1191-1205.
PMID: 30188231
Aims: To describe cost-effectiveness of pembrolizumab plus platinum and pemetrexed chemotherapy in metastatic, non-squamous, NSCLC patients in the US. Materials And Methods: A model is developed utilizing partitioned survival analysis...
7.
Borse R, Kachroo S, Brown C, McCann E, Insinga R
Rheumatol Ther
. 2018 Apr;
5(1):57-73.
PMID: 29633197
Introduction: The aim of this study is to assess the cost-effectiveness of golimumab for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) vs. conventional therapy and other tumor necrosis factor inhibitors...
8.
Insinga R, Joyal C, Goyette A, Galarneau A
BMC Anesthesiol
. 2016 Nov;
16(1):114.
PMID: 27852231
Background: The objective of this analysis is to explore potential impact on operating room (OR) efficiency and incidence of residual neuromuscular blockade (RNMB) with use of sugammadex (Bridion™, Merck &...
9.
Stafford M, Hareendran A, Ng-Mak D, Insinga R, Xu R, Stull D
Health Qual Life Outcomes
. 2012 Jun;
10:65.
PMID: 22691697
Background: To estimate utility values for different levels of migraine pain severity from a United Kingdom (UK) sample of migraineurs. Methods: One hundred and six migraineurs completed the EQ-5D to...
10.
Insinga R, Ng-Mak D, Hanson M
Cephalalgia
. 2011 Oct;
31(15):1570-5.
PMID: 22013140
Background: Data on the average US costs of an outpatient visit, emergency room (ER) visit or hospitalization for migraine are scant, with the most recent available values based on healthcare...